Abstract:Sandra Michiels, 1– 3 Sandra Tricas-Sauras, 2 Adriano Salaroli, 3 Dominique Bron, 3 Philippe Lewalle, 3 Katrijn Vanschoenbeek, 4 Hélène A Poirel, 4 Fati Kirakoya-Samadoulougou 1 1 Center for Research in Epidemiology, Biostatistics and Clinical Research, School of Public Health, Université Libre de Bruxelles, Brussels, Belgium; 2 Center for Research in Social Approaches to Health, School of Public Health, Université Libre de Bruxelles, Brussels, Belgium; 3 Department of Hematology/Oncology, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium; 4 Belgian Cancer Registry, Brussels, Belgium Correspondence: Sandra Michiels, Email ; Purpose: Imatinib adherence and persistence are key components of the successful treatment of Chronic Myeloid Leukemia (CML). In Belgium, there is no study assessing these behaviors at a national level. Our study aimed to provide the first nationwide measure and to identify associated pharmacy-based predictors (age, gender, comorbidities). We also assessed mortality and transplantation incidence according to adherence status. Methods: Based on medico-administrative database linkage, we identified a retrospective Belgian cohort of 1194 patients diagnosed with CML between 2004 and 2016 and treated with imatinib. Adherence was measured over 24 months, considering the proportion of days covered (PDC). Persistence was measured as the time until discontinuation (gap of ≥ 90 days). Multivariable Poisson regression models with robust standard error were conducted to identify predictors associated with adherence (≥ 90% PDC). To identify factors associated with persistence, a multivariable Cox regression was performed. Results: At six months, 60.3% of patients were adherent, declining to 41.5% at 12 months, and to 30.1% at two-year follow-up (n=998). Adherence was greater at a younger age (eg 31– 40 years vs ≥ 75 years, adjusted prevalence ratio (aPR) 1.73; 95% confidence interval (CI): 1.09– 2.77) and among patients with no comorbidity (0 vs ≥ 2 comorbidities (aPR 1.56; 95% CI: 1.11– 2.19). The median persistence was 334.5 days (Q1:200–Q3:505.5); persistence at 24 months was 83.6% (n=998). Only age was associated with higher risk of discontinuation, with adjusted hazard ratio (aHR) of 6.05 for patients ≥ 75 years (95% CI: 5.52– 6.58). Transplants and deaths mainly occurred in patients defined as non-adherent at 24 months. Conclusion: This Belgian nationwide representative study revealed a critical low level of imatinib adherence, which decreased over time even though persistence was high at six months. We pinpointed pharmacy-based predictors that were easily identifiable by health care stakeholders in order to undertake interventions to improve adherence. Plain Language Summary: The introduction of imatinib, a new oral anticancer medication, has transformed chronic myeloid leukemia (CML) from a fatal disease to a chronic disease. However, the success of imatinib partly depends on how long a patient continues to take it (persistence) and the extent to which they take imatinib as prescribed (adherence). Over a 24-month follow-up period, this study aimed to provide an assessment of imatinib adherence and persistence for the first time and to identify associated risk factors. Using pharmacy dispensing data, our study revealed that whilst very few CML patients discontinued imatinib, a considerable proportion struggled to adhere to imatinib recommendations, with a decreasing rate of adherence and persistence over time. We have identified some demographic and clinical characteristics associated with higher risk of poor adherence and early discontinuation. The current study's findings will help healthcare professionals to screen adherence behaviors prospectively and design specific interventions to maintain long-term optimal adherence to imatinib. Keywords: adherence, persistence, imatinib, chronic myeloid leukemia, pharmacy refills data, Belgium Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm accounting for around 15% of newly diagnosed adult leukaemia. 1 Over the past 30 years, the incidence of CML has increased dramatically, reaching 1/100,000 in the global population in 2018. 2 Simultaneously, innovative research and molecular biology have considerably increased survivorship by enabling the accelerating expansion of oral anticancer drugs. 3 In 1998, the introduction of imatinib (Glivec ® ), the first tyrosine kinase BCR-ABL inhibitor (TKI), ushered in a new era of CML treatment, moving it from a fatal disease to a chronic condition. 4 Only 10 years a -Abstract Truncated-

Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs

Healthcare Resource Utilization and Costs Associated with Non-Adherence to Imatinib Treatment in Chronic Myeloid Leukemia Patients.

The Impact of Non-Compliance with Imatinib (IM) Therapy on Health Care Costs.

Efficacy and Safety of Generic Imatinib in Chronic Phase of Chronic Myeloid Leukemia (CP-CML): Experience from a Multi-Center in China

Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU

Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia.

Medication Adherence, Health Care Utilization, and Costs Among Patients Initiating Oral Oncolytics for Multiple Myeloma or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

P684: a multicenter retrospective study in china: clinical characteristics and prognosis of patients with cml-cp treated with different tyrosine kinase inhibitors

Mutation-specific costs of advanced non-small cell lung cancer treatment.

Cost-Effectiveness Of Imatinib In Comparison With Bone Marrow Transplant In Chronic Phase (Cp) Chronic Myeloid Leukaemia (Cml) In China

Treatment Patterns of Chronic Myelogenous Leukemia Patients with Suboptimal Responses to Imatinib

Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US

Treatment Access for Gastrointestinal Stromal Tumor in LMICs

Study of Imatinib Treatment Patterns and Outcomes among Us Veteran Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Treatment patterns and costs among patients with metastatic renal cell carcinoma (mRCC) in the United States: A real-world study using integrated claims and clinical data.

Real-World Study Of Imatinib Treatment Patterns And Outcomes Among Veteran Patients With Chronic Myeloid Leukemia

Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.

Real-World Evaluation of Treatment Patterns and Clinical Outcomes among Patients With Chronic Myeloid Leukemia in Chronic Phase Treated With Asciminib in Clinical Practice in the United States: Real-world asciminib treatment outcomes in CML-CP

A comparative study of different intervention regimens for chronic myelogenous leukemia post allogeneic hematopoietic stem cell transplantation

Imatinib Adherence and Persistence in Patients with Chronic Myeloid Leukemia in Belgium: Evidence from Real-World Data

Impact of a guaranteed access program to imatinib on the survival of patients with chronic myeloid leukemia